Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.

Lin NU, Winer EP.

J Clin Oncol. 2008 Apr 20;26(12):1919-21. doi: 10.1200/JCO.2007.14.7744. Epub 2008 Mar 10. No abstract available.

PMID:
18332468
2.

Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer.

Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN.

J Clin Oncol. 2008 Oct 1;26(28):4679-83. doi: 10.1200/JCO.2008.17.2544. Epub 2008 Jul 28.

PMID:
18662965
3.

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185.

4.

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393.

PMID:
18349391
5.

Ratio of 17HSD1 to 17HSD2 protein expression predicts the outcome of tamoxifen treatment in postmenopausal breast cancer patients.

Jansson A, Delander L, Gunnarsson C, Fornander T, Skoog L, Nordenskjöld B, Stål O.

Clin Cancer Res. 2009 May 15;15(10):3610-6. doi: 10.1158/1078-0432.CCR-08-2599. Epub 2009 Apr 28.

6.

Enhancing the adjuvant treatment of hormone receptor positive breast cancer.

Barry M, Kell MR.

Breast J. 2009 Mar-Apr;15(2):194-8. doi: 10.1111/j.1524-4741.2009.00696.x.

PMID:
19292807
7.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

8.

A question of duration: do patients with early-stage breast cancer need more than five years of adjuvant endocrine therapy?

Burdette-Radoux S, Muss HB.

Clin Breast Cancer. 2009 Jun;9 Suppl 1:S37-41. doi: 10.3816/CBC.2009.s.004. Review.

PMID:
19561005
9.
10.

Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy.

Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A.

Breast Cancer Res Treat. 2009 Jul;116(2):359-69. doi: 10.1007/s10549-008-0223-y. Epub 2008 Oct 22.

PMID:
18941889
11.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
12.

[Correlation of Her-2 overexpression with endocrine status and response to tamoxifen treatment in patients with breast cancer].

Zhang J, Zhang JH, Liu Y, Hao XM, Fang ZX, Li SL.

Zhonghua Yi Xue Za Zhi. 2007 Dec 11;87(46):3268-71. Chinese.

PMID:
18396622
13.

Is triple negative a prognostic factor in breast cancer?

Nishimura R, Arima N.

Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.

PMID:
18369692
14.

Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.

Chlebowski RT.

Breast Cancer Res Treat. 2008 Dec;112 Suppl 1:25-34. doi: 10.1007/s10549-008-0237-5. Epub 2008 Dec 20.

PMID:
19101792
15.

Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer.

Wang S, Yang H, Tong F, Zhang J, Yang D, Liu H, Cao Y, Liu P, Zhou P, Cheng L, Liu M, Guo J.

Gan To Kagaku Ryoho. 2009 Feb;36(2):255-8.

PMID:
19223741
16.

Triple negative breast carcinoma is a prognostic factor in Taiwanese women.

Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, Chen DR.

BMC Cancer. 2009 Jun 18;9:192. doi: 10.1186/1471-2407-9-192.

17.

Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.

Okunade G, Green AR, Ying M, Agrawal A, Paish EC, Aleskandrany M, Winterbottom L, Hassell K, Morgan DA, Ellis IO, Cheung KL.

Crit Rev Oncol Hematol. 2009 Oct;72(1):76-82. doi: 10.1016/j.critrevonc.2009.01.005. Epub 2009 Jun 9.

PMID:
19515574
18.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

PMID:
19380449
19.

Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.

Johansson P, Fohlin H, Arnesson LG, Dufmats M, Nordenskjöld K, Nordenskjöld B, Stål O; South-East Sweden Breast Cancer Study Group.

Acta Oncol. 2009;48(4):504-13. doi: 10.1080/02841860902718754.

PMID:
19235568
20.

An ideal prognostic test for estrogen receptor-positive breast cancer?

Paik S, Tang G, Fumagalli D.

J Clin Oncol. 2008 Sep 1;26(25):4058-9. doi: 10.1200/JCO.2008.16.7528. Epub 2008 Aug 4. No abstract available.

PMID:
18678837

Supplemental Content

Support Center